NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The firm is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The firm has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The firm is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción NRXP?
El precio actual de NRXP es de $2.75, ha increased un 0.56% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de NRX Pharmaceuticals Inc?
NRX Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de NRX Pharmaceuticals Inc?
La capitalización bursátil actual de NRX Pharmaceuticals Inc es $65.4M
¿Es NRX Pharmaceuticals Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para NRX Pharmaceuticals Inc, incluyendo 3 fuerte compra, 6 compra, 1 mantener, 0 venta, y 3 fuerte venta
